<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02337283</url>
  </required_header>
  <id_info>
    <org_study_id>1346.2</org_study_id>
    <secondary_id>2014-004390-16</secondary_id>
    <nct_id>NCT02337283</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets Given Orally Once Daily for 12 Days to Young and Elderly Healthy Male and Female Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Study)(Part 1) and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 After Oral Administration in the Morning Versus Oral Administration in the Evening in Young Healthy Male and Female Volunteers (Randomised, Two-sequence, Open, Two Period, Two-way Cross Over) (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate the safety, tolerability, and pharmacokinetics of&#xD;
      multiple rising doses of BI 425809 tablets given orally once daily for 12 days to young and&#xD;
      elderly healthy male and female volunteers and to compare single dose pharmacokinetics of BI&#xD;
      425809 given in the morning and in the evening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>frequency [N(%)] of subjects with drug related adverse events (AEs)</measure>
    <time_frame>up to 25 days after first drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) only part II</measure>
    <time_frame>up to 96 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma) only part II</measure>
    <time_frame>up to 96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 72 hours after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 216 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval t)</measure>
    <time_frame>up to 216 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) only part II</measure>
    <time_frame>up to 96 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt 0-24(area under the concentration-time curve of the analyte in plasma over a uniform dosing interval t after administration of the first dose)</measure>
    <time_frame>up to 72 hours after first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 425809 very low dose - part I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I only - very low dose tablet, oral administration with 240 ml water, over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - part I</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part I only - placebo tablet, oral administration with 240ml water, over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 low dose - part I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I - low dose tablet, oral administration with 240 ml water, over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 medium dose - part I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I only - medium dose tablet, oral administration with 240 ml water, over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 high dose -part I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I only - high dose tablet, oral administration with 240 ml water, over 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 low dose - part II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II - one low dose tablet on day 1 of visit 2 and 2a</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 425809 very high dose -part I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I only - very high dose tablet, oral administration with 240 ml water, over 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809</intervention_name>
    <description>Tablets</description>
    <arm_group_label>BI 425809 high dose -part I</arm_group_label>
    <arm_group_label>BI 425809 low dose - part I</arm_group_label>
    <arm_group_label>BI 425809 low dose - part II</arm_group_label>
    <arm_group_label>BI 425809 medium dose - part I</arm_group_label>
    <arm_group_label>BI 425809 very high dose -part I</arm_group_label>
    <arm_group_label>BI 425809 very low dose - part I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets</description>
    <arm_group_label>Placebo - part I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Healthy male or female subjects according to the investigatorÂ´s assessment, based on a&#xD;
             complete medical history including a physical examination, vital signs (blood pressure&#xD;
             (BP), pulse rate (PR), 12-lead electrocardiogram (ECG), and clinical laboratory tests&#xD;
&#xD;
          -  age of 18 to 50 years (incl.) for young healthy volunteers or age of 65 to 80 years&#xD;
             (incl.) for elderly healthy volunteers&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 29.9 kg/m2 (incl.)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with good clinical practice (GCP) and local legislation&#xD;
&#xD;
          -  Female subjects who meet any of the following criteria:&#xD;
&#xD;
               1. Surgically sterilised&#xD;
&#xD;
               2. Postmenopausal, defined as at least 1 year of spontaneous amenorrhea (in&#xD;
                  questionable cases a blood sample with simultaneous levels of follicle&#xD;
                  stimulating hormone (FSH) above 40 U/L and estradiol below 30 ng/L is&#xD;
                  confirmatory)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) is deviating from&#xD;
             normal and judged as clinically relevant by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 mmHg in young subjects, and&#xD;
             systolic blood pressure greater than 150 mmHg, diastolic blood pressure greater than&#xD;
             95 mmHg in elderly subjects, or pulse rate outside the range of 50 to 90 bpm&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease judged as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Surgery of the gastrointestinal tract that could interfere with kinetics of the trial&#xD;
             medication&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  Further exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1346.2.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>January 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2015</study_first_posted>
  <last_update_submitted>March 17, 2016</last_update_submitted>
  <last_update_submitted_qc>March 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BI 425809</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

